uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung
NCT ID: NCT02755675
Last Updated: 2016-11-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
120 participants
INTERVENTIONAL
2016-04-30
2023-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Furthermore, uPAR PET/CT will be evaluated in a pilot study in patients with malignant pleural mesothelioma (MPM) (Study II) and large cell neuroendocrine carcinoma of the lung (LCNEC) (Study III) and correlated with immunohistochemical uPAR expression.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
68Ga-NOTA-AE105 PET/CT
One injection of 68Ga-NOTA-AE105 followed by positron emission tomography/computed tomography (PET/CT scan) will be performed before treatment start to evaluate the prognostic value of uPAR PET/CT.
68Ga-NOTA-AE105 PET/CT
Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/CT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
68Ga-NOTA-AE105 PET/CT
Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/CT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically verified NSCLC (Study I)
* Stage IV disease
* Operable disease
* The participants must be capable of understanding and giving full informed written consent
Study II
* Histologically verified MPM (Study II)
* The participants must be capable of understanding and giving full informed written consent
Study III
* Histologically verified LCNEC (Study III)
* The participants must be capable of understanding and giving full informed written consent
Exclusion Criteria
* Pregnancy
* Lactation/breast feeding
* Treatment with neoadjuvant chemotherapy
* Weight above 140 kg
* Allergy to 68Ga-NOTA-AE105
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rigshospitalet, Denmark
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Malene Martini Clausen
MD, PhD, postdoc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Malene M Clausen, MD, PhD
Role: primary
Andreas Kjaer, Professor, MD, DMSc, PhD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AK-2015-LC-1
Identifier Type: -
Identifier Source: org_study_id